Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study
Yugo YamashitaSen YachiMakoto TakeyamaYuji NishimotoIchizo TsujinoJunichi NakamuraNaoto YamamotoHiroko NakataSatoshi IkedaMichihisa UmetsuShizu AikawaHiroya HayashiHirono SatokawaYoshinori OkunoEriko IwataYoshito OgiharaNobutaka IkedaAkane KondoTakehisa IwaiNorikazu YamadaTomohiro OgawaTakao KobayashiMakoto Mo
著者情報
ジャーナル オープンアクセス HTML 早期公開

論文ID: CJ-22-0209

この記事には本公開記事があります。
詳細
抄録

Background: The potential benefit of therapeutic-dose anticoagulation for critically ill patients with coronavirus disease 2019 (COVID-19) is still controversial.

Methods and Results: In the CLOT-COVID study, 225 patients with severe COVID-19 on admission requiring mechanical ventilation or extracorporeal membrane oxygenation were divided into patients with therapeutic-dose anticoagulation (N=110) and those with prophylactic-dose anticoagulation (N=115). There was no significant difference in the incidence of thrombosis between the groups (9.1% vs. 7.8%, P=0.73).

Conclusions: Among a cohort of critically ill patients with COVID-19, approximately half received therapeutic-dose anticoagulation, although it did not show a potential benefit compared with prophylactic-dose anticoagulation.

著者関連情報
© 2022, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top